Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 5Neoplasm Metastasis 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Sarcoma 1Refractory Solid Tumors 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 7Nivolumab 6enfortumab vedotin 5Specimen Handling 5Magnetic Resonance Spectroscopy 5Ipilimumab 4sacituzumab govitecan 3Gemcitabine 3Docetaxel 3CTLA-4 Antigen 3cabozantinib 2Taxes 2Paclitaxel 2Cisplatin 2Carboplatin 2temsirolimus 1relatlimab 1lenvatinib 1eribulin 1avelumab 1atezolizumab 1Valproic Acid 1Sirolimus 1Single Person 1Radiosurgery 1Platinum 1Immunoglobulin G 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × eribulin × 30 days × Clear all
NCT04579224 2026-05-29

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
184 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡